{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:45:15Z","timestamp":1792507515930,"version":"4.5.0"},"reference-count":217,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Autoimmune diseases and other immune-mediated disorders are associated with an increased risk of malignancy, influenced by chronic inflammation, immune dysregulation, and treatment-related factors. Clarifying cancer risk patterns across specific conditions is essential to improve clinical vigilance and inform screening practices. Objective: The aim of this study was to synthesise current evidence on the association between autoimmune and immune-mediated diseases and cancer, with a focus on practical implications for clinicians. Methods: Recent cohort studies, meta-analyses, and expert consensus documents were analysed to describe cancer epidemiology, pathogenic mechanisms, high-risk phenotypes, and treatment considerations across major autoimmune diseases and other immune-mediated conditions. The review covers idiopathic inflammatory myopathies, Sj\u00f6gren\u2019s syndrome, systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid syndrome, ANCA-associated vasculitis, giant cell arteritis, polymyalgia rheumatica, sarcoidosis, mixed connective tissue disease, IgG4-related disease, VEXAS syndrome, and eosinophilic fasciitis. Special attention was given to identifying warning features for underlying malignancy and evaluating cancer screening strategies. Results: The magnitude and distribution of cancer risk vary across diseases. In some conditions such as dermatomyositis, systemic sclerosis or Sj\u00f6gren\u2019s syndrome, increased risk is well established, particularly for haematological and certain solid tumours. However, tumour patterns may differ across populations, and findings are not always consistent. Distinct clinical and serological features help stratify individual cancer risk and may guide the intensity of screening. The first years after disease onset often represent a window of higher vulnerability, during which intensified surveillance may be warranted in selected patients. Conclusions: Cancer risk in autoimmune diseases should be assessed on an individual basis. Awareness of disease-specific risk factors and clinical warning signs supports early recognition of malignancy and informs screening decisions in routine practice.<\/jats:p>","DOI":"10.3390\/jcm14175954","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:09:53Z","timestamp":1756080593000},"page":"5954","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cancer Risk in Autoimmune and Immune-Mediated Diseases: A Narrative Review for Practising Clinicians"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6887-1676","authenticated-orcid":false,"given":"David","family":"Bernal-Bello","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Fuenlabrada, 28942 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Frutos-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Fuenlabrada, 28942 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6138-7558","authenticated-orcid":false,"given":"Miguel \u00c1ngel","family":"Duarte-Mill\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Fuenlabrada, 28942 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Toledano-Mac\u00edas","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Fuenlabrada, 28942 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Jaenes-Barrios","sequence":"additional","affiliation":[{"name":"Arroyomolinos Primary Health Care Center, Arroyomolinos, 28939 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8110-4498","authenticated-orcid":false,"given":"Alejandro","family":"Morales-Ortega","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Fuenlabrada, 28942 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.autrev.2017.07.022","article-title":"Cancer and autoimmune diseases","volume":"16","author":"Giat","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/art.38928","article-title":"Review: Cancer-induced autoimmunity in the rheumatic diseases","volume":"67","author":"Shah","year":"2015","journal-title":"Arthritis Rheum."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"102658","DOI":"10.1016\/j.autrev.2020.102658","article-title":"Eight pillars of oncorheumatology: Crossroads between malignancies and musculoskeletal diseases","volume":"19","author":"Szekanecz","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/cac2.12283","article-title":"The five major autoimmune diseases increase the risk of cancer: Epidemiological data from a large-scale cohort study in China","volume":"42","author":"Zhou","year":"2022","journal-title":"Cancer Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102882","DOI":"10.1016\/j.autrev.2021.102882","article-title":"Autoimmunity and cancer","volume":"20","author":"Masetti","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"101472","DOI":"10.1016\/j.berh.2019.101472","article-title":"The relationships between cancer and autoimmune rheumatic diseases","volume":"34","author":"Cappelli","year":"2020","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.semcancer.2019.06.005","article-title":"Autoimmune diseases and hematological malignancies: Exploring the underlying mechanisms","volume":"64","author":"Hemminki","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1126\/science.1246886","article-title":"Association of the autoimmune disease scleroderma with an immunologic response to cancer","volume":"343","author":"Joseph","year":"2014","journal-title":"Science"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: Integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1474-4422(18)30254-0","article-title":"Classification and management of adult inflammatory myopathies","volume":"17","author":"Milisenda","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_12","first-page":"489","article-title":"Polymyositis","volume":"53","author":"Stertz","year":"1916","journal-title":"Berl. Klin. Wochenschr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40257-015-0120-1","article-title":"Cancer risk in dermatomyositis: A meta-analysis of cohort studies","volume":"16","author":"Olazagasti","year":"2015","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bjd.12564","article-title":"Meta-analysis of the association of dermatomyositis and polymyositis with cancer","volume":"169","author":"Wang","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1093\/rheumatology\/keab166","article-title":"A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies","volume":"60","author":"Oldroyd","year":"2021","journal-title":"Rheumatology"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Liu, S., Zhang, Z., Yan, S., Yang, C., Wang, B., Shen, M., Wang, Z., and Xu, D. (2025). Risk, risk factors, and screening of malignancies in dermatomyositis: Current status and future perspectives. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1503140"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/rheumatology\/kew215","article-title":"Temporal relationship between cancer and myositis identifies two distinctive subgroups of cancers: Impact on cancer risk and survival in patients with myositis","volume":"55","author":"Kang","year":"2016","journal-title":"Rheumatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/rheumatology\/key357","article-title":"The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis","volume":"58","author":"Oldroyd","year":"2019","journal-title":"Rheumatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"103455","DOI":"10.1016\/j.autrev.2023.103455","article-title":"Idiopathic inflammatory myopathies\u2014The burden of disease: Cohort analysis focusing on damage and comorbidities","volume":"22","author":"Campar","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.rdc.2020.05.006","article-title":"Risk factors and cancer screening in myositis","volume":"46","author":"Oddis","year":"2020","journal-title":"Rheum. Dis. Clin. North. Am."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1054\/bjoc.2001.1699","article-title":"Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: A Scottish population-based cohort study","volume":"85","author":"Stockton","year":"2001","journal-title":"Br. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Hsu, J.L., Liao, M.F., Chu, C.C., Kuo, H.C., Lyu, R.K., Chang, H.S., Chen, C.M., Wu, Y.R., Chang, K.H., and Weng, Y.C. (2021). Reappraisal of the incidence, various types and risk factors of malignancies in patients with dermatomyositis and polymyositis in Taiwan. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-83729-5"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41584-023-01045-w","article-title":"International guideline for idiopathic inflammatory myopathy\u2013associated cancer screening: An IMACS initiative","volume":"19","author":"Oldroyd","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/art.42474","article-title":"Association of anti-CCAR1 autoantibodies with decreased cancer risk relative to the general population in patients with anti-transcriptional intermediary factor 1\u03b3-positive dermatomyositis","volume":"75","author":"Fiorentino","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: A consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"103084","DOI":"10.1016\/j.autrev.2022.103084","article-title":"Primary Sj\u00f6gren\u2019s syndrome is associated with increased risk of malignancies besides lymphoma: A systematic review and meta-analysis","volume":"21","author":"Zhong","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2013-203305","article-title":"Primary Sj\u00f6gren\u2019s syndrome and malignancy risk: A systematic review and meta-analysis","volume":"73","author":"Liang","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1001\/archinte.165.20.2337","article-title":"The risk of lymphoma development in autoimmune diseases: A meta-analysis","volume":"165","author":"Zintzaras","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/ard.2005.041186","article-title":"Lymphoma and other malignancies in primary Sj\u00f6gren\u2019s syndrome: A cohort study on cancer incidence and lymphoma predictors","volume":"65","author":"Theander","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/rheumatology\/kei281","article-title":"Incidence of cancer in a cohort of patients with primary Sj\u00f6gren\u2019s syndrome","volume":"45","author":"Lazarus","year":"2006","journal-title":"Rheumatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00296-014-3051-x","article-title":"Identification of lymphoma predictors in patients with primary Sj\u00f6gren\u2019s syndrome: A systematic literature review and meta-analysis","volume":"35","author":"Nishishinya","year":"2015","journal-title":"Rheumatol. Int."},{"key":"ref_32","first-page":"e5","article-title":"MALT lymphoma of minor salivary glands in a Sj\u00f6gren\u2019s syndrome patient: A case report and review of literature","volume":"8","author":"Titsinides","year":"2017","journal-title":"J. Oral. Maxillofac. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13045-017-0464-5","article-title":"Characterization and risk estimate of cancer in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"10","author":"Kostov","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_34","first-page":"e81219","article-title":"Evaluation of the incidence of malignancy in Sj\u00f6gren\u2019s syndrome: A single-center study from Turkey","volume":"17","author":"Cengiz","year":"2025","journal-title":"Cureus"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13075-023-03157-w","article-title":"Causal associations of Sj\u00f6gren\u2019s syndrome with cancers: A two-sample Mendelian randomization study","volume":"25","author":"Jia","year":"2023","journal-title":"Arthritis Res. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Deng, J., Liu, M., Xiao, R., Wang, J., Liao, X., Ye, Z., and Sun, Z. (2022). Risk, incidence, and mortality of breast cancer in primary Sj\u00f6gren\u2019s syndrome: A systematic review and meta-analysis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.904682"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"102987","DOI":"10.1016\/j.autrev.2021.102987","article-title":"Cancer incidence in primary Sj\u00f6gren\u2019s syndrome: Data from the French hospitalization database","volume":"20","author":"Goulabchand","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1573395511309010003","article-title":"Possible mechanisms of lymphoma development in Sj\u00f6gren\u2019s syndrome","volume":"9","author":"Dong","year":"2013","journal-title":"Curr. Immunol. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100098","DOI":"10.1016\/j.jtauto.2021.100098","article-title":"Lymphomagenesis predictors and related pathogenesis","volume":"4","author":"Piedrahita","year":"2021","journal-title":"J. Transl. Autoimmun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.autrev.2004.04.004","article-title":"Hepatitis C virus, Sj\u00f6gren\u2019s syndrome and B-cell lymphoma: Linking infection, autoimmunity and cancer","volume":"4","author":"Tzioufas","year":"2005","journal-title":"Autoimmun. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/bjh.13192","article-title":"Sj\u00f6gren syndrome-associated lymphomas: An update on pathogenesis and management","volume":"168","author":"Nocturne","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e3766","DOI":"10.1097\/MD.0000000000003766","article-title":"Predicting the risk for lymphoma development in Sj\u00f6gren syndrome: An easy tool for clinical use","volume":"95","author":"Fragkioudaki","year":"2016","journal-title":"Medicine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies","volume":"79","author":"Bombardieri","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"R172","DOI":"10.1186\/ar4359","article-title":"Efficacy and safety of rituximab treatment in early primary Sj\u00f6gren\u2019s syndrome: A prospective, multi-center, follow-up study","volume":"15","author":"Carubbi","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40744-019-00183-6","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with rituximab: Analyses of global postmarketing safety data and long-term clinical trial data","volume":"7","author":"Emery","year":"2020","journal-title":"Rheumatol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3899\/jrheum.210441","article-title":"Long-term safety of rituximab in primary Sj\u00f6gren\u2019s syndrome: The experience of a single center","volume":"49","author":"Berardicurti","year":"2022","journal-title":"J. Rheumatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","article-title":"Systemic sclerosis","volume":"401","author":"Volkmann","year":"2023","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/BOR.0000000000000755","article-title":"Cancer and scleroderma: Recent insights","volume":"32","author":"Morrisroe","year":"2020","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1093\/rheumatology\/keae433","article-title":"Systemic sclerosis and cancer in the UK: An epidemiological analysis using the Clinical Practice Research Datalink","volume":"64","author":"Pauling","year":"2025","journal-title":"Rheumatology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/ard.62.8.728","article-title":"Risk of cancer in patients with scleroderma: A population-based cohort study","volume":"62","author":"Hill","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"ref_51","first-page":"563","article-title":"Systemic sclerosis and malignancy","volume":"27","author":"Varga","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.autrev.2012.06.003","article-title":"Lung cancer in scleroderma: Results from an Italian rheumatologic center and review of the literature","volume":"12","author":"Colaci","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/art.37969","article-title":"Cancer incidence in systemic sclerosis: Meta-analysis of population-based cohort studies","volume":"65","author":"Onishi","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.canep.2013.04.014","article-title":"The risk of cancer development in systemic sclerosis: A meta-analysis","volume":"37","author":"Zhang","year":"2013","journal-title":"Cancer Epidemiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/rheumatology\/kes303","article-title":"Systemic sclerosis (scleroderma) and cancer risk: Systematic review and meta-analysis of observational studies","volume":"52","author":"Bonifazi","year":"2013","journal-title":"Rheumatology"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Partouche, L., Goulabchand, R., Maria, A.T.J., Rivi\u00e8re, S., Jorgensen, C., Rigau, V., Bourgier, C., Bessis, D., Le Quellec, A., and Quere, I. (2020). Biphasic temporal relationship between cancers and systemic sclerosis: A clinical series from Montpellier University Hospital and review of the literature. J. Clin. Med., 9.","DOI":"10.3390\/jcm9030853"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Nemes-T\u00f6m\u00f6ri, D., J\u00e1sz, D.K., Tari, D., B\u00f3i, B., \u00c1goston-Szab\u00f3, \u00c1., Sz\u0171cs, G., and Majai, G.E. (2025). Malignancy in systemic sclerosis: A multicenter retrospective study. Biomedicines, 13.","DOI":"10.3390\/biomedicines13040993"},{"key":"ref_58","first-page":"445","article-title":"Scleroderma and malignancy: A review of the current evidence","volume":"69","author":"Siau","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1002\/art.21225","article-title":"Risk of lung cancer in scleroderma: A population-based cohort study","volume":"52","author":"Chatterjee","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_60","first-page":"6230138","article-title":"Haematological malignancies in systemic sclerosis patients: Case reports and review of the world literature","volume":"2017","author":"Colaci","year":"2017","journal-title":"Case Rep. Rheumatol."},{"key":"ref_61","first-page":"e66653","article-title":"Characterizing the links between systemic sclerosis and breast cancer","volume":"16","author":"Dutt","year":"2024","journal-title":"Cureus"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/BOR.0000000000000222","article-title":"Cancer and scleroderma: A paraneoplastic disease with implications for malignancy screening","volume":"27","author":"Shah","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3899\/jrheum.160817","article-title":"Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: Analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening","volume":"44","author":"Lazzaroni","year":"2017","journal-title":"J. Rheumatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.autrev.2017.03.012","article-title":"Novel risk factors related to cancer in scleroderma","volume":"16","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"103167","DOI":"10.1016\/j.autrev.2022.103167","article-title":"Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE)","volume":"21","author":"Carbonell","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.autrev.2017.05.023","article-title":"Auto-antibodies and cancer in systemic sclerosis","volume":"16","author":"Boonstra","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/art.40065","article-title":"Anti-RNPC-3 antibodies as a marker of cancer-associated scleroderma","volume":"69","author":"Shah","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/rheumatology\/kead520","article-title":"Anti-nuclear valosin-containing protein-like autoantibody is associated with calcinosis and higher risk of cancer in systemic sclerosis","volume":"63","author":"Colobran","year":"2024","journal-title":"Rheumatology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1136\/annrheumdis-2018-212999","article-title":"Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer","volume":"77","author":"Igusa","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.40893","article-title":"Protective effect against cancer of antibodies to the large subunits of both RNA polymerases I and III in scleroderma","volume":"71","author":"Shah","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e004492","DOI":"10.1136\/rmdopen-2024-004492","article-title":"Autoantibodies, cutaneous subset and immunosuppressants contribute to the cancer risk in systemic sclerosis","volume":"10","author":"Tonutti","year":"2024","journal-title":"RMD Open"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s12016-022-08930-4","article-title":"Systemic sclerosis association with malignancy","volume":"63","author":"Lepri","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/acr.24076","article-title":"Incidence, risk factors, and outcomes of cancer in systemic sclerosis","volume":"72","author":"Morrisroe","year":"2020","journal-title":"Arthritis Care Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/1744666X.2021.1847641","article-title":"Cancer risk in systemic sclerosis: Identifying risk and managing high-risk patients","volume":"16","author":"Fragoulis","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaut.2012.12.009","article-title":"Cancer risk in systemic lupus: An updated international multi-centre cohort study","volume":"42","author":"Bernatsky","year":"2013","journal-title":"J. Autoimmun."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1150.e1","DOI":"10.1016\/j.amjmed.2010.08.006","article-title":"Malignancy in systemic lupus erythematosus: A nationwide cohort study in Taiwan","volume":"123","author":"Chen","year":"2010","journal-title":"Am. J. Med."},{"key":"ref_77","first-page":"887","article-title":"Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California","volume":"19","author":"White","year":"2008","journal-title":"Cancer Causes Control."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1002\/art.30483","article-title":"High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: A long-term follow-up study in a Danish cohort","volume":"63","author":"Dreyer","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/03009742.2017.1384054","article-title":"Increased incidence of cancer in systemic lupus erythematosus: A Finnish cohort study with more than 25 years of follow-up","volume":"47","author":"Tallbacka","year":"2018","journal-title":"Scand. J. Rheumatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1177\/0961203321990106","article-title":"Increased cancer risk in patients with cutaneous lupus erythematosus and systemic lupus erythematosus compared with the general population: A Danish nationwide cohort study","volume":"30","author":"Westermann","year":"2021","journal-title":"Lupus"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1177\/0961203313520060","article-title":"Lung, liver, prostate, bladder malignancies risk in systemic lupus erythematosus: Evidence from a meta-analysis","volume":"23","author":"Ni","year":"2014","journal-title":"Lupus"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Cao, L., Tong, H., Xu, G., Liu, P., Meng, H., Wang, J., Zhao, X., Tang, Y., and Jin, J. (2015). Systemic lupus erythematosus and malignancy risk: A meta-analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0122964"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.semarthrit.2021.09.009","article-title":"Risk of malignancy in patients with systemic lupus erythematosus: Systematic review and meta-analysis","volume":"51","author":"Clarke","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00432-015-2032-0","article-title":"Systemic lupus erythematosus and malignancies risk","volume":"142","author":"Mao","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Zhang, M., Wang, Y., Wang, Y., Bai, Y., and Gu, D. (2022). Association between systemic lupus erythematosus and cancer morbidity and mortality: Findings from cohort studies. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.860794"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/art.1780400424","article-title":"Non-Hodgkin\u2019s lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus","volume":"40","author":"Andersen","year":"1997","journal-title":"Arthritis Rheum."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/03009740252937568","article-title":"Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus","volume":"31","author":"Yin","year":"2002","journal-title":"Scand. J. Rheumatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.autrev.2009.07.004","article-title":"Malignancies in systemic lupus erythematosus","volume":"9","author":"Kiss","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/BOR.0000000000000202","article-title":"Malignancies in systemic lupus erythematosus: A 2015 update","volume":"27","author":"Goobie","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1177\/0961203307079045","article-title":"Monoclonal gammopathy in systemic lupus erythematosus","volume":"16","author":"Ali","year":"2007","journal-title":"Lupus"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s13075-018-1760-3","article-title":"The risks of cancer development in systemic lupus erythematosus (SLE) patients: A systematic review and meta-analysis","volume":"20","author":"Song","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.autrev.2014.03.001","article-title":"Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A meta-analysis of the literature","volume":"13","author":"Zard","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/ijc.33185","article-title":"A meta-analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale","volume":"148","author":"Clifford","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00296-024-05623-3","article-title":"Malignancy in systemic lupus erythematosus: Relation to disease characteristics in 92 patients\u2014A single center retrospective study","volume":"44","author":"Dziedzic","year":"2024","journal-title":"Rheumatol. Int."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.rdc.2014.04.005","article-title":"Systemic lupus erythematosus and malignancies: A review article","volume":"40","author":"Clarke","year":"2014","journal-title":"Rheum. Dis. Clin. North. Am."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3109\/00016489.2013.800228","article-title":"Impact of head and neck malignancies on risk factors and survival in systemic lupus erythematosus","volume":"133","author":"Chang","year":"2013","journal-title":"Acta Otolaryngol."},{"key":"ref_97","first-page":"6270","article-title":"Thyroid cancer in systemic lupus erythematosus: A meta-analysis","volume":"7","author":"Zhang","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.cgh.2013.11.007","article-title":"Increased risk of hepatobiliary cancers after hospitalization for autoimmune disease","volume":"12","author":"Castro","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1007\/s10067-019-04660-9","article-title":"Risk of pancreatic cancer in patients with systemic lupus erythematosus: A meta-analysis","volume":"38","author":"Seo","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/0961203313497118","article-title":"Cancer complicating systemic lupus erythematosus\u2014A dichotomy emerging from a nested case-control study","volume":"22","author":"Dey","year":"2013","journal-title":"Lupus"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.rdc.2020.05.005","article-title":"Cancer and systemic lupus erythematosus","volume":"46","author":"Ladouceur","year":"2020","journal-title":"Rheum. Dis. Clin. North. Am."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nrrheum.2016.23","article-title":"DNA-damaging autoantibodies and cancer: The lupus butterfly theory","volume":"12","author":"Noble","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Weisbart, R.H., Chan, G., Jordaan, G., Noble, P.W., Liu, Y., Glazer, P.M., Nishimura, R.N., and Hansen, J.E. (2015). DNA-dependent targeting of cell nuclei by a lupus autoantibody. Sci. Rep., 5.","DOI":"10.1038\/srep12022"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.imlet.2015.01.007","article-title":"Heat shock protein 27 and its regulatory molecules express differentially in SLE patients with distinct autoantibody profiles","volume":"164","author":"Rai","year":"2015","journal-title":"Immunol. Lett."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/iid3.443","article-title":"The complex role of AIM2 in autoimmune diseases and cancers","volume":"9","author":"Zhu","year":"2021","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13075-025-03482-2","article-title":"Cancer incidence and the influence of immunosuppressive agents in Korean patients with systemic lupus erythematosus: A retrospective cohort study","volume":"27","author":"Cho","year":"2025","journal-title":"Arthritis Res. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1136\/annrheumdis-2012-202099","article-title":"Lymphoma risk in systemic lupus: Effects of disease activity versus treatment","volume":"73","author":"Bernatsky","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_108","first-page":"620","article-title":"Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14,832 patients with systemic lupus erythematosus: A nested case-control study","volume":"56","author":"Hsu","year":"2017","journal-title":"Rheumatology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/ard.2006.067777","article-title":"Antilarials may influence the risk of malignancy in systemic lupus erythematosus","volume":"66","author":"Ugarte","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13075-020-02228-6","article-title":"The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: A nested case-control study","volume":"22","author":"Guo","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1080\/07853890.2021.1981547","article-title":"Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: A systematic review and meta-analysis of prospective studies","volume":"53","author":"Li","year":"2021","journal-title":"Ann. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.berh.2008.12.007","article-title":"Malignancy in systemic lupus erythematosus: What have we learned?","volume":"23","author":"Bernatsky","year":"2009","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1177\/0961203315575587","article-title":"What investigations are needed to optimally monitor for malignancies in SLE?","volume":"24","author":"Clarke","year":"2015","journal-title":"Lupus"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: A meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/ar2404","article-title":"A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis","volume":"10","author":"Smitten","year":"2008","journal-title":"Arthritis Res. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/annrheumdis-2013-204851","article-title":"Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"74","author":"Mercer","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s10067-019-04882-x","article-title":"Lung cancer in rheumatoid arthritis: Is there a need for better risk assessment and screening?","volume":"39","author":"Fragoulis","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Moosic, K.B., Ananth, K., Andrade, F., Feith, D.J., Darrah, E., and Loughran, T.P. (2022). Intersection between large granular lymphocyte leukemia and rheumatoid arthritis. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.869205"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood.2023023593","article-title":"IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation","volume":"143","author":"Hong","year":"2024","journal-title":"Blood"},{"key":"ref_121","first-page":"551","article-title":"Low incidence of colorectal cancer in patients with rheumatoid arthritis","volume":"14","author":"Kauppi","year":"1996","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Tian, G., Liang, J.N., Wang, Z.Y., and Zhou, D. (2014). Breast cancer risk in rheumatoid arthritis: An updated meta-analysis. Biomed. Res. Int., 2014.","DOI":"10.1155\/2014\/453012"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/art.1780400906","article-title":"Rheumatoid arthritis and the risk of malignancy","volume":"40","author":"Cibere","year":"1997","journal-title":"Arthritis Rheum."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1136\/annrheumdis-2015-208263","article-title":"Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden","volume":"75","author":"Frisell","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.semarthrit.2007.01.002","article-title":"Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain","volume":"37","author":"Llorca","year":"2007","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7326\/0003-4819-120-1-199401010-00006","article-title":"Incidence of cancer among men with the Felty syndrome","volume":"120","author":"Gridley","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semcancer.2013.12.001","article-title":"Lymphoma development in patients with autoimmune and inflammatory disorders\u2014What are the driving forces?","volume":"24","author":"Baecklund","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199305063281806","article-title":"Reversible lymphomas associated with Epstein\u2013Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis","volume":"328","author":"Kamel","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1200\/JCO.1996.14.6.1943","article-title":"Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases","volume":"14","author":"Salloum","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2022.11.043","article-title":"Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: Methotrexate, alkylating agents, biologics, and small molecule inhibitors","volume":"88","author":"Kreher","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1001\/jama.296.18.2203-b","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"296","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/2012.jama.10857","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: A meta-analysis","volume":"308","author":"Tayar","year":"2012","journal-title":"JAMA"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1158\/1055-9965.EPI-21-0125","article-title":"Tumor necrosis factor inhibitors and the risk of cancer among older Americans with rheumatoid arthritis","volume":"30","author":"Beachler","year":"2021","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3324\/haematol.2018.213991","article-title":"Increased incidence of cancer in the follow-up of obstetric antiphospholipid syndrome within the NOH-APS cohort","volume":"105","author":"Gris","year":"2020","journal-title":"Haematologica"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Nipu, M.A.I., Kundu, S., Alam, S.S., Dina, A.N., Hasan, M.A., Khan, M., Khalil, M.I., Hossan, T., and Islam, M.A. (2023). Anticardiolipin antibodies in patients with cancer: A case-control study. Cancers, 15.","DOI":"10.3390\/cancers15072087"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_140","first-page":"3326","article-title":"Systematic review of observational studies reporting antiphospholipid antibodies in patients with solid tumors","volume":"4","author":"Tayar","year":"2020","journal-title":"Blood Adv."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.autrev.2010.10.006","article-title":"Solid cancer, antiphospholipid antibodies, and venous thromboembolism","volume":"10","author":"Font","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.semcancer.2019.07.019","article-title":"Antiphospholipid antibodies and antiphospholipid syndrome in cancer: Uninvited guests in troubled times","volume":"64","author":"Islam","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1191\/0961203303lu328oa","article-title":"High prevalence of antiphospholipid antibodies in Asian cancer patients with thrombosis","volume":"12","author":"Yoon","year":"2003","journal-title":"Lupus"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jcrc.2014.02.005","article-title":"Antiphospholipid antibodies in critically ill patients with cancer: A prospective cohort study","volume":"29","author":"Vassalo","year":"2014","journal-title":"J. Crit. Care"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.autrev.2006.06.012","article-title":"The catastrophic antiphospholipid (Asherson\u2019s) syndrome and malignancies","volume":"6","author":"Miesbach","year":"2006","journal-title":"Autoimmun. Rev."},{"key":"ref_146","first-page":"e76481","article-title":"Cancer history, antiphospholipid syndrome, and lupus anticoagulant: A perfect storm for thrombosis","volume":"16","author":"Carpintieri","year":"2024","journal-title":"Cureus"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1111\/j.1538-7836.2004.01011.x","article-title":"Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway","volume":"2","author":"Miller","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13075-024-03345-2","article-title":"Malignancy is increased in patients with antineutrophil cytoplasmic antibody-associated vasculitis in China","volume":"26","author":"Han","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s11739-024-03577-9","article-title":"Unveiling cancer risk in ANCA-associated vasculitis: Result from the Turkish Vasculitis Study Group (TRVaS)","volume":"19","author":"Bilgin","year":"2024","journal-title":"Intern. Emerg. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.3899\/jrheum.181438","article-title":"Malignancies in patients with antineutrophil cytoplasmic antibody-associated vasculitis: A population-based cohort study","volume":"47","author":"Heijl","year":"2020","journal-title":"J. Rheumatol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1002\/art.39317","article-title":"Incidence of malignancies in patients with antineutrophil cytoplasmic antibody-associated vasculitis diagnosed between 1991 and 2013","volume":"67","author":"Rahmattulla","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_152","first-page":"100","article-title":"Malignancies in Wegener\u2019s granulomatosis: Incidence and relation to cyclophosphamide therapy in a cohort of 293 patients","volume":"35","author":"Faurschou","year":"2008","journal-title":"J. Rheumatol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s10238-024-01475-0","article-title":"ANCA-associated vasculitis and lung cancer: An immunological perspective","volume":"24","author":"Li","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.coi.2012.12.003","article-title":"T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment","volume":"25","author":"Crespo","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/1529-0131(199904)42:4<751::AID-ANR19>3.0.CO;2-D","article-title":"Wegener\u2019s granulomatosis associated with renal cell carcinoma","volume":"42","author":"Tatsis","year":"1999","journal-title":"Arthritis Rheum."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/rheumatology\/keh374","article-title":"Malignancy is increased in ANCA-associated vasculitis","volume":"43","author":"Pankhurst","year":"2004","journal-title":"Rheumatology"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/rheumatology\/kep009","article-title":"Cancer preceding Wegener\u2019s granulomatosis: A case-control study","volume":"48","author":"Faurschou","year":"2009","journal-title":"Rheumatology"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/BOR.0000000000000448","article-title":"Antineutrophil cytoplasmic antibody-associated vasculitis and malignancy","volume":"30","author":"Bajema","year":"2018","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","article-title":"Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis","volume":"76","author":"Rizzo","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1001\/jama.2020.10155","article-title":"Polymyalgia rheumatica and giant cell arteritis","volume":"324","author":"Buttgereit","year":"2020","journal-title":"JAMA"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1016\/S2665-9913(23)00300-4","article-title":"Large vessel giant cell arteritis","volume":"6","author":"Sandovici","year":"2024","journal-title":"Lancet Rheumatol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.semarthrit.2014.06.004","article-title":"Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: A systematic review and meta-analysis","volume":"44","author":"Ungprasert","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/rheumatology\/keq040","article-title":"Cancer risk in patients hospitalised with polymyalgia rheumatica and giant cell arteritis: A follow-up study in Sweden","volume":"49","author":"Ji","year":"2010","journal-title":"Rheumatology"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1093\/rheumatology\/keab328","article-title":"Haematological malignancies in giant cell arteritis: A French population-based study","volume":"60","author":"Greigert","year":"2021","journal-title":"Rheumatology"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Dar, L., Ben-Shabat, N., Tiosano, S., Watad, A., McGonagle, D., Komaneshter, D., Cohen, A., Bragazzi, N.L., and Amital, H. (2021). The incidence and predictors of solid- and hematological malignancies in patients with giant cell arteritis: A large real-world database study. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18147595"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4081\/reumatismo.2018.1031","article-title":"The real evidence for polymyalgia rheumatica as a paraneoplastic syndrome","volume":"70","author":"Muller","year":"2018","journal-title":"Reumatismo"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1136\/annrheumdis-2013-203465","article-title":"Is cancer associated with polymyalgia rheumatica? A cohort study in the General Practice Research Database","volume":"73","author":"Muller","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2147\/OARRR.S116036","article-title":"Polymyalgia rheumatica and cancer: A critical review of the literature","volume":"8","author":"Manzo","year":"2016","journal-title":"Open Access Rheumatol."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Gorlen, T.F., Brittain, J.M., \u00d8stergaard, M., Fischer, B.M., D\u00f8hn, U.M., and Terslev, L. (2024). Low incidence of malignancy in patients with suspected polymyalgia rheumatica or giant cell arteritis, examined with FDG-PET\/CT. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1309905"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/reum.2023.124336","article-title":"Polymyalgia rheumatica and cancer: Surveillance duration and other points to ponder","volume":"61","author":"Manzo","year":"2023","journal-title":"Reumatologia"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/bjc.1974.64","article-title":"The incidence of malignant tumours in patients with respiratory sarcoidosis","volume":"29","author":"Brincker","year":"1974","journal-title":"Br. J. Cancer"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/bjc.1986.199","article-title":"The sarcoidosis\u2013lymphoma syndrome","volume":"54","author":"Brincker","year":"1986","journal-title":"Br. J. Cancer"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Patt, Y.S., Ben-Shabat, N., Sharif, K., Patt, C., Elizur, Y., Arow, M., Cohen, A.D., Watad, A., McGonagle, D., and Amital, H. (2024). The association between sarcoidosis and malignancy: A comprehensive population-based cohort study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13237045"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","article-title":"Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: A pooled analysis within the InterLymph Consortium","volume":"111","author":"Smedby","year":"2008","journal-title":"Blood"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1183\/09031936.98.12040906","article-title":"Sarcoidosis and cancer revisited: A long-term follow-up study of 555 Danish sarcoidosis patients","volume":"12","author":"Hommelgaard","year":"1998","journal-title":"Eur. Respir. J."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/acr.22941","article-title":"Risk of malignancy among patients with sarcoidosis: A population-based cohort study","volume":"69","author":"Ungprasert","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/thx.52.10.892","article-title":"Risk of malignant neoplasms in patients with pulmonary sarcoidosis","volume":"52","author":"Seersholm","year":"1997","journal-title":"Thorax"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0140-6736(03)12888-7","article-title":"Sarcoidosis","volume":"361","author":"Baughman","year":"2003","journal-title":"Lancet"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/joim.12991","article-title":"Drug-induced sarcoidosis: An overview of the WHO pharmacovigilance database","volume":"288","author":"Lhote","year":"2020","journal-title":"J. Intern. Med."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1378\/chest.14-1475","article-title":"Sarcoidosis and cancer risk: Systematic review and meta-analysis of observational studies","volume":"147","author":"Bonifazi","year":"2015","journal-title":"Chest"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3899\/jrheum.210588","article-title":"Risk of cancer among sarcoidosis patients with biopsy-verified nonnecrotizing granulomatous inflammation: Population-based cohort study","volume":"49","author":"Faurschou","year":"2022","journal-title":"J. Rheumatol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.berh.2016.03.002","article-title":"Mixed connective tissue disease","volume":"30","author":"Gunnarsson","year":"2016","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/joim.13752","article-title":"Clinical presentation, course, and prognosis of patients with mixed connective tissue disease: A multicenter retrospective cohort","volume":"295","author":"Chevalier","year":"2024","journal-title":"J. Intern. Med."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/MS9.0000000000001462","article-title":"Mixed connective tissue and ovarian cancer: A case report","volume":"86","author":"Kudsi","year":"2023","journal-title":"Ann. Med. Surg."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s10067-005-1159-9","article-title":"Malignant thymoma associated with mixed connective tissue disease: A case report","volume":"25","author":"Lin","year":"2006","journal-title":"Clin. Rheumatol."},{"key":"ref_187","first-page":"843","article-title":"Mixed connective tissue disease in a patient with Castleman disease and Hodgkin lymphoma: Excellent clinical response to rituximab","volume":"106","author":"Fuertes","year":"2015","journal-title":"Actas Dermo-Sifiliogr."},{"key":"ref_188","first-page":"568","article-title":"A case of hepatocellular carcinoma associated with mixed connective tissue disease","volume":"104","author":"Monoe","year":"2007","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/annrheumdis-2019-216561","article-title":"The 2019 American College of Rheumatology\/European League Against Rheumatism classification criteria for IgG4-related disease","volume":"79","author":"Wallace","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s40744-021-00326-8","article-title":"Malignancy risk of immunoglobulin G4-related disease: Evidence from a large cohort multicenter retrospective study","volume":"8","author":"Liu","year":"2021","journal-title":"Rheumatol. Ther."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2169\/internalmedicine.53.1342","article-title":"Incidence of malignancies in patients with IgG4-related disease","volume":"53","author":"Hirano","year":"2014","journal-title":"Intern. Med."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"841","DOI":"10.4143\/crt.2019.151","article-title":"Autoimmune diseases and gastric cancer risk: A systematic review and meta-analysis","volume":"51","author":"Song","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Tang, H., Yang, H., Zhang, P., Wu, D., Zhang, S., Zhao, J., Peng, L., Chen, H., Fei, Y., and Zhang, X. (2020). Malignancy and IgG4-related disease: The incidence, related factors and prognosis from a prospective cohort study in China. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-61585-z"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/jgh.15809","article-title":"Nationwide epidemiological survey of immunoglobulin G4-related disease with malignancy in Japan","volume":"37","author":"Sumimoto","year":"2022","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1007\/s10620-021-07179-9","article-title":"Correlation of autoimmune pancreatitis and malignancy: Systematic review and meta-analysis","volume":"67","author":"Haghbin","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13075-021-02652-2","article-title":"The risk of malignancy in patients with IgG4-related disease: A systematic review and meta-analysis","volume":"24","author":"Yu","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1002\/art.39773","article-title":"Association of IgG4-related disease with history of malignancy","volume":"68","author":"Wallace","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/ajg.2012.465","article-title":"Risk of cancer in patients with autoimmune pancreatitis","volume":"108","author":"Shiokawa","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3109\/s10165-011-0520-x","article-title":"Risk of malignancies in IgG4-related disease","volume":"22","author":"Yamamoto","year":"2012","journal-title":"Mod. Rheumatol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.reuma.2023.10.006","article-title":"VEXAS syndrome: Clinical manifestations, diagnosis, and treatment","volume":"20","author":"Ferrada","year":"2024","journal-title":"Reumatol. Clin. (Engl. Ed.)"},{"key":"ref_201","first-page":"3591","article-title":"VEXAS syndrome","volume":"137","author":"Grayson","year":"2021","journal-title":"Blood"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood.2020010286","article-title":"Novel somatic mutations in UBA1 as a cause of VEXAS syndrome","volume":"137","author":"Poulter","year":"2021","journal-title":"Blood"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1182\/blood.2020010177","article-title":"Therapeutic options in VEXAS syndrome: Insights from a retrospective series","volume":"137","author":"Bourbon","year":"2021","journal-title":"Blood"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood.2019000940","article-title":"Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria","volume":"136","author":"Sun","year":"2020","journal-title":"Blood"},{"key":"ref_206","first-page":"70","article-title":"Diffuse fasciitis with eosinophilia: A new syndrome?","volume":"87","author":"Shulman","year":"1974","journal-title":"Trans. Assoc. Am. Physicians"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.autrev.2014.01.019","article-title":"Diagnosis and classification of eosinophilic fasciitis","volume":"13","author":"Grau","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.hemonc.2013.12.003","article-title":"Eosinophilic fasciitis as a paraneoplastic syndrome: A case report and review of the literature","volume":"7","author":"Haddad","year":"2014","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0049-0172(88)90008-X","article-title":"Eosinophilic fasciitis: Clinical spectrum and therapeutic response in 52 cases","volume":"17","author":"Lakhanpal","year":"1988","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/1346-8138.15561","article-title":"Characteristics of Japanese patients with eosinophilic fasciitis: A brief multicenter study","volume":"47","author":"Yamamoto","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/archderm.1991.01680050106013","article-title":"Concurrent eosinophilic fasciitis and cutaneous T-cell lymphoma. Eosinophilic fasciitis as a paraneoplastic syndrome of T-cell malignant neoplasms?","volume":"127","author":"Chan","year":"1991","journal-title":"Arch. Dermatol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.2169\/internalmedicine.9300-21","article-title":"Eosinophilic fasciitis with hypereosinophilia as the initial clinical manifestation of peripheral T-cell lymphoma, not otherwise specified","volume":"61","author":"Okuyama","year":"2022","journal-title":"Intern. Med."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3346\/jkms.2000.15.3.346","article-title":"Eosinophilic fasciitis preceding relapse of peripheral T-cell lymphoma","volume":"15","author":"Kim","year":"2000","journal-title":"J. Kor. Med. Sci."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jdin.2023.01.011","article-title":"Eosinophilic fasciitis may present as a paraneoplastic syndrome of hematological malignancies\u2014A systematic review","volume":"11","author":"Chohan","year":"2023","journal-title":"JAAD Int."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1440-0960.2007.00415.x","article-title":"Eosinophilic fasciitis as a paraneoplastic phenomenon associated with metastatic colorectal carcinoma","volume":"49","author":"Philpott","year":"2008","journal-title":"Australas. J. Dermatol."},{"key":"ref_216","first-page":"9928","article-title":"Eosinophilic fasciitis and breast cancer: A case report highlighting recurrence signals","volume":"16","author":"Maione","year":"2024","journal-title":"Dermatol. Rep."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jdcr.2021.09.010","article-title":"Eosinophilic fasciitis as a paraneoplastic syndrome in melanoma","volume":"17","author":"Rea","year":"2021","journal-title":"JAAD Case Rep."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/17\/5954\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:34:32Z","timestamp":1760034872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/17\/5954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":217,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["jcm14175954"],"URL":"https:\/\/doi.org\/10.3390\/jcm14175954","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,23]]}}}